| III-01 Lisa Amann Stepwise Covariate Modelling (SCM) versus Full Random Effects Modelling (FREM) for covariate modelling of correlated covariates exemplified with tigecycline and liver function markers |
| III-02 Kyle Baron Development and validation of open-source pharmacometrics software using an iterative software development life cycle methodology: the pmtables R package for submission-ready table generation. |
| III-03 Julie Bertrand Model-based approaches for bioequivalence studies with only one-time point measured drug concentration |
| III-04 Sabrina Boutaghou On the influence of sampling schemes on the demonstration of bioequivalence |
| III-05 Núria Buil Bruna Cheat sheet for pharmacometrics communication |
| III-06 Jung-woo CHAE The effect of CYP2D6 phenotypes on the pharmacokinetics of propafenone: a systematic review and meta-analysis |
| III-07 Estelle Chasseloup Individual Model Averaging to increase robustness in drug effect estimation |
| III-08 Chao Chen Translational modelling and estimation of probability of molecule success on balance of pharmacology benefit and safety risk |
| III-09 David Cristinacce PoPy: Population PKPD Analysis in Python |
| III-10 David Fairman Towards Industrialisation of Probability of Pharmacological Success (PoPS) |
| III-11 Manu Francis Subspace MCMC algorithm for Bayesian parameter estimation of hierarchical PK/PD models in Pumas |
| III-12 Leonid Gibiansky Calibration of an IgG turnover model using data from administration of monoclonal antibodies targeting FcRn receptor |
| III-13 Jan Grzegorzewski PK-DB: pharmacokinetics database for individualized and stratified computational modeling |
| III-14 Benjamin Guiastrennec Improving the reproducibility of NONMEM-based pharmacometric analyses |
| III-15 Woojin Jung Web based platform for clinical pharmacokinetic consultation service (CPCS) with Non-linear Mixed Effect Model |
| III-16 Lina Keutzer Machine learning for covariate selection and prediction of pharmacokinetic data illustrated with rifampicin |
| III-17 Niklas Korsbo Latexify.jl - An ecosystem for automatically transcribing Pumas and Julia objects into renderable equations. |
| III-18 Anne Kümmel IQnca: An open-source R package for efficient and reproducible non-compartmental analysis in R |
| III-19 Silvia Maria Lavezzi Evaluation of efficacy predictors and probability of pharmacological success for a novel compound to treat parasitic disease proposed for first-time-into-human |
| III-20 Félicien Le Louedec Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr |
| III-21 Christopher Rackauckas Automated Machine Learning Acceleration of Pharmacometrics Models in Pumas with JuliaSim |
| III-22 Thi Quyen Tran Overview of Korean Pharmacometrics Modeling Library and web-based pharmacometrics platform |
| III-23 Anastasia Tsyplakova Development and validation of a population pharmacokinetic model for donepezil |
| III-24 Lisa van der Heijden Extrapolation of Phase 0 microdosing trials: a naïve pooled data modelling approach. |
| III-25 Zhengguo Xu Estimators and Confidence Intervals of f2 Using Bootstrap Methodology for the Comparison of Dissolution Profiles |
| III-26 Simone Zannoni Investigating the identifiability of one-stage IVIVC population models for extended-release dosage forms |
| III-27 Elisa Borella Vaborem pharmacokinetics and dose rationale in children |
| III-28 Elisa Borella Oritavancin pharmacokinetics and dose rationale in children |
| III-29 Salvatore D'Agate Model-based evaluation of beta-lactams in neonatal and paediatric sepsis |
| III-30 Eva Degraeuwe Population pharmacokinetic modeling of lisinopril at steady-state in hypertensive pediatric patients with mild to moderate renal impairment |
| III-31 Esther Encinas Simulation of systemic exposure after multiple ocular administration of bilastine ophthalmic solution for safety assessment in children |
| III-32 Aline Engbers Lack of pharmacokinetic interaction between doxapram and caffeine for the treatment of preterm infants with apnea |
| III-33 Alan Faraj Phase-3 dose selection of marzeptacog alfa (activated) in children enabled by model-informed drug development techniques |
| III-34 Kinga Fiebig Prospective evaluation of a novel model-based dosing guideline for gentamicin in preterm and term neonates |
| III-35 Anthony Gebhart A semi-physiologically based pharmacokinetics approach to predict hepatic and gut wall intrinsic clearances of midazolam in pediatric patients: preliminary results filling the gap between preterm neonates and infants above 1 year |
| III-36 Iztok Grabnar Pharmacokinetic-pharmacodynamic model of fentanyl sedation in children with severe acute bronchiolitis |
| III-37 Ana-Marija Grisic Population pharmacokinetic model of avelumab in a pediatrics population |
| III-38 Soumya Perinparajah A Novel Mechanistic Mathematical Model for CD19+ B Cell Reconstitution after Paediatric Haematopoietic Stem Cell Transplantation |
| III-39 Maša Roganović Population pharmacokinetic modelling of cyclosporine in paediatric kidney transplant patients using routine TDM data |
| III-40 Rajendra Singh Determination of the individual pharmacokinetic exposure parameter uncertainty to support of pediatric exposure-response trial design |
| III-41 Rajendra Singh Population pharmacokinetic analysis of deutetrabenazine (AUSTEDO) in children and adolescents with Tourette Syndrome |
| III-42 Erik Sjögren Lumenfantrine Exposure in Malnourished Children: PBPK modeling applied for Predictions and Dose Adjustments |
| III-43 Tomás Sou Caplacizumab Model-Based Dosing Recommendations In Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura |
| III-44 Marinda van de Kreeke Quantifying requirements for additional sedatives in critically-ill children using a repeated time to event analysis |
| III-45 Louvina van der Laan Pharmacokinetics of para-aminosalicylic acid in children treated for multidrug-resistant tuberculosis. |
| III-46 Yunjiao Wu Pre- and postnatal maturation are important for fentanyl exposure in preterm and term newborns: a pooled population pharmacokinetic study |
| III-47 Jurij Aguiar Zdovc Model-based individualization of ustekinumab dosing in Crohn's disease |
| III-48 Orwa Albitar A Pharmacokinetic and Pharmacodynamic Model of Cyclosporine among Malaysian Renal Transplant Patients |
| III-49 Muhammad Waqar Ashraf A population pharmacokinetic model to quantify the role of in-vivo CYP2D6 activity in codeine metabolism for model informed precision dosing in ambulatory surgical patients. |
| III-50 Rebecca Baillie Reuse of a published model to support compassionate use of novel drug formulation for a rare disorder |
| III-51 Amina Bensalem The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition |
| III-52 Rene Boosman The pemetrexed exposure-neutropenia relationship, paving the way to a safe administration in patients with an impaired renal function |
| III-53 Divakar Budda Prediction of CNS Target Engagement of Pain reliving Drugs in Health and Chronic Pain conditions |
| III-54 Laura Bukkems Population pharmacokinetics of Haemate P describing the interaction between factor VIII and Von Willebrand Factor levels in perioperative patients with von Willebrand Disease |
| III-55 Vera Bukkems A combined modelling approach to assess the efficacy and safety of doravirine in pregnant women |
| III-56 Elisa Calvier TMDD model to extrapolate free target reduction from competitor data in healthy volunteers to another drug in patients in order to select active dose range for phase II trials |
| III-57 Fernando Carreño Modelling of Dose-Response-Time Data Using a Population k-PD approach for Linerixibat, a Locally Acting Small Molecule with Minimal Systemic Absorption |
| III-58 Myriam Chartoire Development of mechanistic models for analysis and interpretation of cough challenge test data |
| III-59 Perrine Courlet Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control |
| III-60 Wilbert de Witte Continuous Time Markov Modelling in Systemic Lupus Erythematosus |
| III-61 Tayebeh Esmaeili Rivaroxaban Population Pharmacokinetics Modeling in Iranian Patients |
| III-62 Yu Fu A novel hemodynamic systems model to quantify pharmacodynamic effects on heart rate and contractility |
| III-63 Frédéric Gaspar A step towards Ticagrelor individualization based on pharmacokinetic approaches: which place for Physiologically-Based Modelling? |
| III-64 Mélanie Guhl Model-based analysis of PK equivalence: assessing the impact of model misspecification |
| III-65 Khalid Iqbal A PK-PD modelling and simulation-based evaluation of tedizolid dosing strategies for immunocompromised patients |
| III-67 Ranita Kirubakaran Matters close to the heart: adaptation of a tacrolimus model to inform tacrolimus therapy using the PRIOR approach |
| III-68 Christine Juliane Kleist Homoarginine population kinetics |
| III-69 Jane Knöchel Markov model demonstrates the importance of fibrosis distribution on clinical trial design in NAFLD/NASH |
| III-70 Niklas Kroemer Development and evaluation of D-optimal 2x2 checkerboard designs for identification of pharmacodynamic drug interactions |
| III-71 Julia Larsson A second-generation challenge model of TNFa turnover with LPS provocations and drug intervention |
| III-72 Li Li Model-Based Approach for assessing the Effect of Anti-Drug Antibodies on the PK of Therapeutic Proteins |
| III-73 Qiang Lu Semi-mechanistic Population Pharmacokinetic/Pharmacodynamic (Pop PK/PD) Modeling of Dupilumab on Nasal Congestion (NC) Score in Patients with Chronic Rhinosinusitis with Nasal Polyposis |
| III-74 Bastien Martin In silico clinical trial simulation shows amelioration of ischemia-reperfusion injury in ST-elevation myocardial infarction via inhibition of reactive oxygen species production |
| III-75 Saikumar Matcha Population Pharmacokinetics of Unbound Phenytoin after Administration of IV Fosphenytoin And Oral Phenytoin in Pediatric Patients. |
| III-76 Nicola Melillo Development and validation of a physiologically-based pharmacokinetic model of the imaging biomarker gadoxetate for prospective prediction of hepatic transporters drug-drug interactions |
| III-77 Yomna Nassar Quantifying the dynamics of the modulatory effect of CYP3A perpetrators on hepatic CYP3A activity using a nonlinear mixed-effects model of microdosed midazolam and its metabolite 1-hydroxymidazolam |
| III-78 Karine Rodriguez-Fernandez Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics |
| III-79 Benjamin Schneider A Quantitative Systems Pharmacology Model for Bedside Optimization of ACE Inhibitor Dose Scheduling in Veterinary Cardiology |
| III-80 Daniel Seeler Towards understanding vascular (dys)regulation by linking endothelial cell morphology and blood vessel geometry |
| III-81 Sejung Hwang Effect of CYP2D6 genotype on pharmacokinetics and pharmacodynamics of carvedilol for the heart rate reduction in healthy subjects |
| III-82 Manna Semere Gebreyesus Population pharmacokinetics of esomeprazole in pregnant women with preterm preeclampsia |
| III-83 Monica Simeoni A Model Based Meta-Analysis for Bridging Treatment Doses of Rheumatoid Arthritis with Axial Spondyloarthritis |
| III-84 Leonid Stolbov A QSP approach to investigate the glucose-insulin dynamic following dapagliflozin treatment in patients with type 2 diabetes mellitus |
| III-85 David Ternant In-depth description of target-mediated pharmacokinetics of infliximab in inflammatory bowel disease patients |
| III-86 Wisse van Os Targeted temperature management reduces CYP2C19 metabolism: a population pharmacokinetic study using pantoprazole |
| III-87 Zhigang Wang Pharmacokinetic-Pharmacodynamic Model-Based Exploration of Alternative Ustekinumab Dosage Regimens for Patients with Crohn’s Disease |
| III-88 Liang Yang A quantitative pharmacology model for CB1 receptor mediated by Gi Gs protein competition |
| III-89 Miren Zamacona Population pharmacokinetic and exposure-response models for dapirolizumab pegol in patients with systemic lupus erythematosus |
| III-90 Chiara Zecchin mPBPK and PD modelling and simulation to predict drug and pharmacodynamic effect at site of action and guide the design of a phase 2A/B study |
